Telomerase-Specific Oncolytic Adenovirus Expressing p53 Gene Stimulating CD8+ Memory T Cells in Pancreatic Cancer

Masashi Hashimoto; Shinji Kuroda; Nobuhiko Kanaya; Yoshihiko Kakiuchi; Satoru Kikuchi; Hiroshi Tazawa; Shunsuke Kagawa; Yasuo Urata; Toshiyoshi Fujiwara

Telomerase-Specific Oncolytic Adenovirus Expressing p53 Gene Stimulating CD8+ Memory T Cells in Pancreatic Cancer

Masashi Hashimoto
, Shinji Kuroda
, Nobuhiko Kanaya
, Yoshihiko Kakiuchi
, Satoru Kikuchi
, Hiroshi Tazawa
, Shunsuke Kagawa
, Yasuo Urata
, Toshiyoshi Fujiwara

Research output: Contribution to journal › Article › peer-review

Abstract

Pancreatic cancer has poor prognosis despite the various developed multimodal treatment strategies. Currently, neoadjuvant chemotherapy and immunotherapy have attracted substantial attention as effective treatment strategies. However, amplifying immune response with existing treatments is difficult. We developed telomerase-specific oncolytic adenoviruses (OAs), including OBP-301 that is currently tested in a clinical trial of combined anti-PD-1 antibody and p53-armed OBP- 301 variant(OBP-702). OAs have immune-modulation functions and induce CD8+ T cells into tumors by releasing immunogenic cell death markers, such as extracellular adenosine triphosphate. Here, we investigated the effectiveness of OBP- 702 in pancreatic cancer treatments, focusing on the influence on CD8+ memory T cells.

Original language	English
Pages (from-to)	1127-1129
Number of pages	3
Journal	Gan to kagaku ryoho. Cancer & chemotherapy
Volume	49
Issue number	10
Publication status	Published - Oct 1 2022

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

ASJC Scopus subject areas

General Medicine

Cite this

@article{894650944b6c4382be42ace4c903bb18,

title = "Telomerase-Specific Oncolytic Adenovirus Expressing p53 Gene Stimulating CD8+ Memory T Cells in Pancreatic Cancer",

abstract = "Pancreatic cancer has poor prognosis despite the various developed multimodal treatment strategies. Currently, neoadjuvant chemotherapy and immunotherapy have attracted substantial attention as effective treatment strategies. However, amplifying immune response with existing treatments is difficult. We developed telomerase-specific oncolytic adenoviruses (OAs), including OBP-301 that is currently tested in a clinical trial of combined anti-PD-1 antibody and p53-armed OBP- 301 variant(OBP-702). OAs have immune-modulation functions and induce CD8+ T cells into tumors by releasing immunogenic cell death markers, such as extracellular adenosine triphosphate. Here, we investigated the effectiveness of OBP- 702 in pancreatic cancer treatments, focusing on the influence on CD8+ memory T cells.",

author = "Masashi Hashimoto and Shinji Kuroda and Nobuhiko Kanaya and Yoshihiko Kakiuchi and Satoru Kikuchi and Hiroshi Tazawa and Shunsuke Kagawa and Yasuo Urata and Toshiyoshi Fujiwara",

year = "2022",

month = oct,

day = "1",

language = "English",

volume = "49",

pages = "1127--1129",

journal = "Gan to kagaku ryoho. Cancer \& chemotherapy",

issn = "0385-0684",

publisher = "Japanese Journal of Cancer and Chemotherapy Publishers Inc.",

number = "10",

}

TY - JOUR

T1 - Telomerase-Specific Oncolytic Adenovirus Expressing p53 Gene Stimulating CD8+ Memory T Cells in Pancreatic Cancer

AU - Hashimoto, Masashi

AU - Kuroda, Shinji

AU - Kanaya, Nobuhiko

AU - Kakiuchi, Yoshihiko

AU - Kikuchi, Satoru

AU - Tazawa, Hiroshi

AU - Kagawa, Shunsuke

AU - Urata, Yasuo

AU - Fujiwara, Toshiyoshi

PY - 2022/10/1

Y1 - 2022/10/1

N2 - Pancreatic cancer has poor prognosis despite the various developed multimodal treatment strategies. Currently, neoadjuvant chemotherapy and immunotherapy have attracted substantial attention as effective treatment strategies. However, amplifying immune response with existing treatments is difficult. We developed telomerase-specific oncolytic adenoviruses (OAs), including OBP-301 that is currently tested in a clinical trial of combined anti-PD-1 antibody and p53-armed OBP- 301 variant(OBP-702). OAs have immune-modulation functions and induce CD8+ T cells into tumors by releasing immunogenic cell death markers, such as extracellular adenosine triphosphate. Here, we investigated the effectiveness of OBP- 702 in pancreatic cancer treatments, focusing on the influence on CD8+ memory T cells.

AB - Pancreatic cancer has poor prognosis despite the various developed multimodal treatment strategies. Currently, neoadjuvant chemotherapy and immunotherapy have attracted substantial attention as effective treatment strategies. However, amplifying immune response with existing treatments is difficult. We developed telomerase-specific oncolytic adenoviruses (OAs), including OBP-301 that is currently tested in a clinical trial of combined anti-PD-1 antibody and p53-armed OBP- 301 variant(OBP-702). OAs have immune-modulation functions and induce CD8+ T cells into tumors by releasing immunogenic cell death markers, such as extracellular adenosine triphosphate. Here, we investigated the effectiveness of OBP- 702 in pancreatic cancer treatments, focusing on the influence on CD8+ memory T cells.

UR - https://www.scopus.com/pages/publications/85140571249

UR - https://www.scopus.com/pages/publications/85140571249#tab=citedBy

M3 - Article

C2 - 36281608

AN - SCOPUS:85140571249

SN - 0385-0684

VL - 49

SP - 1127

EP - 1129

JO - Gan to kagaku ryoho. Cancer & chemotherapy

JF - Gan to kagaku ryoho. Cancer & chemotherapy

IS - 10

ER -

Telomerase-Specific Oncolytic Adenovirus Expressing p53 Gene Stimulating CD8+ Memory T Cells in Pancreatic Cancer

Abstract

UN SDGs

ASJC Scopus subject areas

Other files and links

Fingerprint

Cite this